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Abstract Complement activation plays an important role in
the pathogenesis of pneumonia. We hypothesized that
inhibition of the complement system in the lungs by repe-
ated treatment with nebulized plasma-derived human C1-
esterase inhibitor reduces pulmonary complement activation
and subsequently attenuates lung injury and lung inﬂam-
mation. This was investigated in a rat model of severe
Streptococcus pneumoniae pneumonia. Rats were
intra–tracheally challenged with S. pneumoniae to induce
pneumonia. Nebulized C1-esterase inhibitor or saline
(control animals) was repeatedly administered to rats, 30
min before induction of pneumonia and every 6 h thereafter.
Rats were sacriﬁced 20 or 40 h after inoculation with bac-
teria. Brochoalveolar lavage ﬂuid and lung tissue were
obtained for measuring levels of complement activation
(C4b/c), lung injury and inﬂammation. Induction of pneu-
monia was associated with pulmonary complement activa-
tion (C4b/c at 20 h 1.24 % [0.56–2.59] and at 40 h 2.08 %
[0.98–5.12], compared to 0.50 % [0.07–0.59] and 0.03 %
[0.03–0.03] in the healthy control animals). The functional
fraction of C1-INH was detectable in BALF, but no effect
was found on pulmonary complement activation (C4b/c at
20 h 0.73 % [0.16–1.93] and at 40 h 2.38 % [0.54–4.19]).
Twenty hours after inoculation, nebulized C1-esterase
inhibitor treatment reduced total histology score, but this
effect was no longer seen at 40 h. Nebulized C1-esterase
inhibitor did not affect other markers of lung injury or lung
inﬂammation. In this negative experimental animal study,
severe S. pneumoniae pneumonia in rats is associated with
pulmonary complement activation. Repeated treatment with
nebulized C1-esterase inhibitor, although successfully
delivered to the lungs, does not affect pulmonary comple-
ment activation, lung inﬂammation or lung injury.
Keywords Pneumonia ● Complement ● Complement
activation ● Pulmonary complement activation ● Lung injury ●
Pulmonary inﬂammation ● Lung inﬂammation ● C1-esterase
inhibitor ● Complement inhibition
Introduction
Severe pneumonia is associated with high morbidity and
mortality [1]. While early and adequate antimicrobial therapy
remains the cornerstone of treatment, additive therapeutic
strategies may further improve outcome. The complement
cascade plays an important role in pulmonary host defense
against invading pathogens [2]. While complement protein
deﬁciencies are associated with severe and recurrent pul-
monary infections [3, 4], excessive complement activation
has been found to be associated with development of lung
injury [5–7]. Thus, a balanced regulation of the local com-
plement system seems to be important to maintain home-
ostasis during severe pneumonia.
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The complement cascade is under control of various
proteins. C1-esterase inhibitor (C1-INH) is the major
negative regulator of the classical and lectin complement
pathway [8]. During acute inﬂammation, a relative C1-INH
deﬁciency may occur [9]. This could result from inactiva-
tion due to elastase released from host neutrophils combined
with invading pathogens resulting in overwhelming stimuli
[10, 11]. C1-INH has been used as treatment in various
disease models [12–18], such as myocardial infarction and
septic shock, showing beneﬁcial results on myocardial
infarction size and improved renal function.
C1-INH treatment is scarcely investigated in models of
lung injury. Despite a reduction in pulmonary complement
activation in one experiment, lung inﬂammation and lung
injury were not affected [19, 20]. In these experiments C1-
INH was administered systemically, possibly resulting in
too low local levels to have beneﬁcial effects. We hypo-
thesized that locally applied C1-INH, by repeated neb-
ulization, inhibits pulmonary complement activation and
subsequently mitigates lung injury. This was investigated in
a placebo-controlled experimental study in a well-




Our institutional animal care and use committee approved
the study protocol. Procedures were followed through in
agreement with the institutional Standards for Human Care
and Use of Laboratory Animals. A ﬂow diagram of the
study is presented in Fig. 1.
Induction of Pneumonia
Thirty-two male Sprague–Dawley rats (Harlan, The Hague,
The Netherlands) weighing 250–300 g were challenged
intra–tracheally with 250 µL containing~1.0 × 107 colony
forming units (CFU) of S. pneumoniae serotype 3 (Amer-
ican Type Culture Collection 6303, Rockville, MD, USA).
Administration of this solution was performed under mild
anesthesia (3 % isoﬂurane in oxygen) using a trans–oral
miniature nebulizer (Penn–Century, Philadelphia, PA,
USA). Sixteen rats received sterile saline (0.9 % NaCl) and
served as controls.
Treatment with C1-INH
Rats were randomized to receive treatment with either 200 IU
of C1-INH in a volume of 2 ml (Sanquin, Amsterdam, The
Netherlands) or an equal volume of placebo (0.9% NaCl)
using an Aeroneb Pro nebulizer (Aerogen Ltd., Galway, Ire-
land). Rats with pneumonia and healthy controls were
repeatedly exposed to nebulized C1-INH or placebo, as
described previously [21], using an exposure system in which
the noses of the rats are directly exposed to the nebulized C1-
INH or saline. The nebulizing system consists of a circular
central chamber distributing the aerosols to the connected
restraint tubes (CHT 249 restraint tube, CH technologies Inc.,
Westwood, NJ, USA). The system allows for nebulization of
several rats simultaneously. Nebulization was performed 30
min before induction of pneumonia and every 6 h thereafter.
Rats were sacriﬁced 20 or 40 h after inoculation to investigate
C1-INH treatment at two time points.
Primary and Secondary Outcomes
For our primary outcome we measured activated comple-
ment component 4 (C4b/c) in bronchoalveolar lavage ﬂuid
Fig. 1 Consort diagram of the
study
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(BALF) as marker of classical/lectin pathway activation in
the pulmonary compartment. Secondary endpoints were
lung injury and lung inﬂammation. Lung injury was deter-
mined measuring total histopathology score, relative lung
wet weight, total protein, and neutrophil inﬂux. A pro-
inﬂammatory cytokine proﬁle of the lung provided the level
of pulmonary inﬂammation (tumor necrosis factor (TNF)-α,
interleukin (IL)-6 and cytokine-induced neutrophil che-
moattractant (CINC)-3).
Harvesting of Blood, BALF, and Lung Tissue
After 20 or 40 h, rats with S. pneumoniae pneumonia and
controls were anesthetized by intraperitoneally injecting a
solution containing 90 mg/kg ketamine (Nimatek, Eurovet
Animal Health BV, Bladel, The Netherlands), 0.125 mg/kg
dexmedetomidine (Dexdomitor, Janssen Pharmaceutica NV,
Beerse, The Netherlands) and 0.05mg/kg atropine (Atropi-
nesulfate, Centrafarm BV, Etten–Leur, The Netherlands).
Thereafter, rats were exsanguinated by puncture of the
inferior vena cava. Blood was collected in a 4 mL Ethyle-
nediaminetetraacetic acid (EDTA) tube (Vacutainer, Becton
Dickinson B.V., Breda, The Netherlands) and thereafter
centrifuged for 10 min at 1800 × g at 4 °C. The lungs were
removed in total and after ligation of the right lung, the left
lung was lavaged three times with 2 mL of sterile saline
containing 10% EDTA. After removal, the top of the right
lung was used for histopathology and was ﬁxed in 4 %
buffered formaldehyde and subsequently embedded in par-
afﬁn. One part of the right lung was used for relative lung
wet weight determination and the rest was homogenized for
CFU counts. Cell counts in BALF were performed using a
hematocytometer (Z2 Coulter Particle Counter; Beckman
Coulter Corporation, USA) and Giemsa–stained cytospin
preparations (Dade Behring AG, Dudingen, Switzerland)
were used for differential counts. Hereafter, BALF was
centrifuged for 10 min at 300 × g at 4 °C.
Bacterial Outgrowth in Lung and Blood
CFU counts in lung homogenates were determined by
culturing 10-fold dilutions on blood agar plates. Dis-
semination of bacteria was determined by culturing 100 μL
of blood directly obtained from the vena cava inferior on
blood agar plates (AMC, Amsterdam, The Netherlands).
Blood agar plates were incubated at 37 °C in 5 % CO2 and
CFUs were counted the following day.
Lung Homogenization
To determine pulmonary inﬂammation in lung homogenate,
lungs were weighed and homogenized in 4 times its weight
of sterile normal saline (i.e., 4 × lung weight [mg] in μL)
using a tissue homogenizer (Biospec Products, Bartlesville,
OK, USA). Lung homogenates were then diluted 1:1 in
lysis buffer (105 nmol/L NaCl; 15 mmol/L Tris; 1 mmol/L
MgCl2–H2O; 1 mmol/L CaCl2; 1 % Triton X-100; and
100 μg/mL of a mixture of protease inhibitors; pepstatin A,
leupeptin, and aprotinin) and after centrifuging a cell and
debris free supernatant was obtained.
Assays
Human C1-INH antigen and activity, as well as activated
complement factor 4 were measured using an ELISA
(Sanquin, Amsterdam, The Netherlands) as described before
[22]. The assay for activated complement factor 4 is referred
to as C4b/c since no distinction is made between C4b, C4bi
and C4c. Levels of C4b/c are depicted in percentage (%) of
maximal level of activation in plasma. Levels of TNF-α, IL-
6, and CINC-3 in lung homogenate were measured using
ELISA (R&D Systems, Abingdon, UK).
Histopathology Scores
Parafﬁn embedded lung tissue sections of four µm thick
were stained with haematoxylin and eosin. Thereafter, tis-
sue sections were scored by a pathologist blinded to group
randomization. To score lung injury, different variables of
the lung sections were quantitatively analyzed. Interstitial
inﬂammation, endothelialitis, bronchitis, edema, pleuritis,
and thrombus formation were graded on a scale of 0–4 (0,
absent; 1, mild; 2, moderate; 3, severe; 4, very severe) as
described previously [23]. The total histopathological lung
injury score comprises the sum of scores for all variables.
Statistical Analysis
Data of individual rats are shown in graphs with median
showing variety in distribution. In text data are presented as
median with range. To investigate the effect of 20 or 40 h of
S. pneumoniae pneumonia on pulmonary complement acti-
vation, lung injury and inﬂammation, rats were compared to
their respective healthy control. To investigate the effect of
treatment with nebulized plasma-derived human C1-INH on
S. pneumoniae pneumonia induced pulmonary complement
activation, lung injury and inﬂammation, C1-INH treated
rats were compared with placebo treated rats at 20 and 40 h,
respectively. For comparisons of two groups, student’s t-test
or Mann Whitney U was used according to data distribution.
For multiple group comparisons, ANOVA with Bonferroni
post-hoc test or Kruskall–Wallis test with a Dunn’s post-hoc
correction was used according to the data distribution.
Statistical analysis was performed using GraphPad Prism
version 5 (GraphPad software Inc, La Jolla, CA, USA). A p-
value of <0.05 was considered statistically signiﬁcant.
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Results
Animals
All animals survived the experiment until the moment of
sacriﬁce (Fig. 1). After inoculation with S. pneumoniae, rats
developed severe pneumonia with dyspnea, and macro-
scopic inﬁltrates on post-mortem examination. Histopatho-
logic analysis showed clear signs of pneumonia (Fig. 2) and
total histology score was increased upon inoculation with S.
pneumoniae after 20 and 40 h (Fig. 3a). Bacterial outgrowth
of S. pneumoniae was observed in lung homogenates of
infected rats (Fig. 3b) and the incidence of bacterial dis-
semination from the pulmonary compartment to the blood,
increased from 12.5 % of the rats sacriﬁced 20 h after
inoculation to 62.5 % of the rats sacriﬁced after 40 h.
Twenty hours after inoculation with S. pneumoniae a
non–signiﬁcant decrease in bodyweight was observed. After
40 h this decrease in bodyweight was more pronounced and
signiﬁcant compared to healthy rats (Fig. 3c).
C1-INH Treatment and Pulmonary Complement
Activation
In rats treated with nebulized C1-INH, signiﬁcantly
increased C1-INH levels (antigen and activity) were mea-
sured in BALF, compared to saline controls. This
observation was found both at 20 and 40 h (Figs. 4a, b).
Pneumonia resulted in augmented levels of C4b/c in BALF
increasing over time. Despite the local C1-INH availability
(including its active fraction), pulmonary C4b/c levels were
not signiﬁcantly attenuated at 20 and 40 h (Fig. 4c).
Lung Inﬂammation and Injury
C1-INH treatment showed a signiﬁcant reduction of the
total histology score at 20 h. This reduction was abrogated
after 40 h of pneumonia (Fig. 3a). Relative lung wet weight
(Fig. 5a), total protein (Fig. 5b), and neutrophil inﬂux
(Fig. 5c) were signiﬁcantly increased at both 20 and 40 h.
No effect of C1-INH treatment was seen on these lung
injury parameters. In addition, bacterial outgrowth remained
unchanged in C1-INH treated rats with pneumonia com-
pared to their saline controls (12.5 % at 20 h and 62.5 % at
40 h).
TNF-α and IL-6 were signiﬁcantly increased in rats
sacriﬁced after 40 h, but not after 20 h (Figs. 6a, b,
respectively). In contrast, CINC-3 levels were signiﬁcant
increased at 20 h, though no differences were present at 40 h
(Fig. 6c). Nebulized C1-INH did not reduce inﬂammatory
markers IL-6 and CINC-3 (Figs. 6b, c, respectively), though
higher levels of TNF-α were observed 40 h after inoculation
in the C1-INH treated group (Fig. 6a).
Fig. 2 Haematoxylin and eosin
stained lung sections of rats
nebulized with saline 20 h after
inoculation with sterile saline a;
or Streptococcus pneumoniae b;
and 40 h after inoculation with
sterile saline c; or Streptococcus
pneumoniae d
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Discussion
In this experiment we demonstrate that severe pneumonia in
rats is associated with complement activation in the lungs,
measured by increased levels of complement C4b/c. After
repetitive nebulization of C1-INH, both antigen and activity
levels of C1-INH were detectable in the lungs. Despite these
increased levels of C1-INH in the lungs, no effects on
pulmonary complement activation (C4b/c), lung inﬂam-
mation or lung injury were found.
In lung injury, local inﬂammatory reactions occur that
comprises a complicated interaction between pneumocytes,
inﬂammatory cells, cytokines, acute phase proteins, and the
complement system [24]. In different animal models,
Fig. 3 Total histopathology
score a bacterial outgrowth in
the lung b and change in
bodyweight c in rats after 20 or
40 h in healthy animals (circles)
or animals with Streptococcus
pneumoniae pneumonia
(squares). Animals were treated
with either nebulized sterile
saline (clear) or nebulized
C1–INH (black). Bars represent
median. *p< 0.05; **p< 0.01,
and ***p< 0.001
Fig. 4 Total amount of human
C1-INH antigen in BALF.
a functional human C1-INH in
BALF b C4b/c in BALF as a
percentage of maximal activated
C4b/c in plasma c in rats after
20 or 40 h in healthy animals
(circles) or animals with
Streptococcus pneumoniae
pneumonia (squares). Animals
were treated with either
nebulized sterile saline (clear) or
nebulized C1-INH (black). Bars
represent median. *p< 0.05;
**p< 0.01, and ***p< 0.001
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complement activation was shown to result in tissue
damage and organ dysfunction, including lung injury.
Inhibition of complement activation was found to prevent
these deleterious effects [12–18]. In this study, with rats we
examined the extent and consequences of complement
activation in the lungs during severe pneumonia.
So far, only two studies investigated inhibition of local
complement activation in models of lung injury [19, 20].
Treatment with C1-INH reduced complement C3a levels,
but not C5a levels in BALF in a rat model of transfusion-
related acute lung injury [20]. A beneﬁcial effect was found
on the total histology score, but no effect was seen on
vascular leakage or inﬂammation in the lung. In another
study, in a two-hit model of pneumonia and injurious
ventilation in rats, systemic treatment with C1-INH did not
affect pulmonary complement activation, lung inﬂammation
Fig. 5 Relative lung wet weight.
a total protein BALF b and
neutrophil inﬂux in BALF c in
rats after 20 or 40 h in healthy
animals (circles) or animals with
Streptococcus pneumoniae
pneumonia (squares). Animals
were treated with either
nebulized sterile saline (clear) or
nebulized C1-INH (black). Bars
represent median. *p< 0.05;
**p< 0.01, and ***p< 0.001
Fig. 6 TNF-α a IL-6 b and
CINC-3 c in BALF in rats after
20 or 40 h in healthy animals
(circles) or animals with
Streptococcus pneumoniae
pneumonia (squares). Animals
were treated with either
nebulized sterile saline (clear) or
nebulized C1-INH (black). Bars
represent median. *p< 0.05;
**p< 0.01, and ***p< 0.001
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or lung injury [19]. Notably, in these two studies, C1-INH
was administered systemically, which could have resulted
in too low local levels of C1-INH. We chose to administer
C1-INH locally by repetitive nebulization in our rat model
of severe pneumonia. Nevertheless, we also found no
beneﬁcial effects, except for a short-lasting effect on the
total histology score.
The lack of effect of nebulized C1-INH in our experi-
ment may have several explanations. Aggravation of the
pneumonia during the course of the disease might have
overwhelmed the effects of administered C1-INH. Indeed, a
beneﬁcial effect was seen on the total histology score after
20 h, which is, at least in part in line with the effects
observed in a previous study [20]. In our study this bene-
ﬁcial effect was no longer present after 40 h. Another
explanation might be that complement activation is a ﬁrst
line of defense in ﬁghting encapsulated bacteria and other
humoral (e.g., antibodies and cytokines) and cellular
immune responses eventually take over, contributing to
increased tissue damage. However, no conclusions to that
point can be drawn from these results, since this reduction
in total histology score was not accompanied by an effect on
pulmonary complement activation or on other endpoints.
It is also possible that nebulized C1-INH does not reach
the smaller airways and alveoli of infected lungs. The rats
with pneumonia had lower levels of C1-INH antigen and its
active fraction in BALF compared to their healthy coun-
terparts. This may have been caused by high frequent but
low tidal breathing due to the pneumonia, scavenging of
C1-INH by mucus in the airways or increased consumption
of C1-INH due to the heightened inﬂammatory state and
increased bacterial activity. Furthermore, increased proteo-
lytic activity by elastase in the lung, catalyzed by an
increased neutrophil inﬂux, could cleave, and thus inacti-
vate, the C1-INH protein. Such an increased proteolytic
activity could also result in pulmonary complement acti-
vation further down the cascade [25]. In this situation, C1-
INH, which regulates complement activation at the top of
the cascade, will not be effective. Therefore, future
experiments directed at pulmonary complement inhibition
in lung injury models should consider different targets of
intervention in the complement cascade (e.g. anti-C5
antibodies).
The nebulizer used for administration of drugs in this
experiments has been applied in several previous rat lung
injury studies in our laboratory. In these studies the effects
of nebulized anti-coagulant and pro-ﬁbrinolytic agents on
pulmonary coagulopathy were investigated. Signiﬁcant
reduction in coagulation and increased ﬁbrinolysis was
described [21, 26]. This, at least, indicates good distribution
of the aerosolized agents by the nebulizing technique used.
In the present experiment we found C1-INH in BALF,
though levels were below normal levels of C1-INH found in
plasma. Therefore, one could state that underdosage may be
another explanation for the absence of pulmonary comple-
ment inhibition. However, our C1-INH measurements are
not corrected for dilution caused by the lung lavage. The
dilution therefore largely underestimates the real con-
centration of C1-INH in the lung.
The increase of CINC-3 after 20 h of pneumonia and
increased levels of TNF-α and IL-6 after 40 h of pneumonia
probably reﬂects the inﬂammatory reactions during the S.
pneumoniae pneumonia. However, the reason why TNF-α
levels increase after 40 h of C1-INH treatment compared to
saline controls remains unclear. It may reﬂect toxic effects of
C1-INH, as has previously described by Müller et al. [20].
Previous studies showed C1-INH in high dosages to be able
to induce inﬂammation rather than attenuate it [20, 27]. Since
no increase in lung inﬂammation was observed in C1-INH
treated groups in our study, with high levels of C1-INH in
BALF, toxicity of C1-INH in this experiment seems unlikely.
The timing of C1-INH administration may be disputed.
In our model, C1-INH was administrated before induction
of pneumonia (pre-treatment), which is not the case in real
life. Furthermore, antibiotics, as part of treatment following
the guidelines, were not used during the experiment. For
these reasons this study may be less clinically relevant.
However, as C1-INH was ineffective in this model, it is not
very likely that C1-INH administration later in the course of
pneumonia would have revealed different results.
Although we were unable to reject our hypothesis, and
taken into account the limitations of the study as described
above, we consider our ﬁndings important for publication.
Publication of negative animal studies is known to be very
important in reducing publication bias in medical-scientiﬁc
literature [28].
In conclusion, this is a negative experimental animal
study in which repetitive nebulization with C1-INH, a
potent inhibitor of the complement system, was examined.
C1-INH was unable to attenuate pneumonia-induced pul-
monary complement activation, lung inﬂammation and lung
injury in severe S. pneumonia pneumonia in rats.
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